These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2431 related articles for article (PubMed ID: 29054544)
1. [Abnormalities of DNA repair and gynecological cancers]. Auguste A; Leary A Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544 [TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
7. The current status of PARP inhibitors in ovarian cancer. McLachlan J; George A; Banerjee S Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873 [TBL] [Abstract][Full Text] [Related]
8. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106 [TBL] [Abstract][Full Text] [Related]
9. [DNA repair as a therapeutic target]. Eberst L; Brahmi M; Cassier PA Bull Cancer; 2017 Nov; 104(11):988-998. PubMed ID: 29132681 [TBL] [Abstract][Full Text] [Related]
10. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868 [TBL] [Abstract][Full Text] [Related]
11. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225 [TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307 [TBL] [Abstract][Full Text] [Related]
15. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer. Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A; Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer. Nirsimloo R; Gourley C Expert Rev Anticancer Ther; 2016 Jun; 16(6):597-603. PubMed ID: 27115428 [TBL] [Abstract][Full Text] [Related]
17. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Tewari KS; Eskander RN; Monk BJ Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965 [TBL] [Abstract][Full Text] [Related]
18. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257 [TBL] [Abstract][Full Text] [Related]
19. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
20. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]